clinical trial · NCT05398640
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Unresectable MelanomaMetastatic MelanomaOOS AMTAGVI
brief summary
The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.
started
—
primary completion
—
completion
—
last updated
Apr 20, 2026
detailed description
This program provides access to OOS AMTAGVI (lifileucel) that does not meet commercial release criteria but does meet Iovance clinical trial release criteria. Patients will be followed for safety and efficacy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol